Skye Bioscience (Nasdaq: SKYE) is a biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Backed by specialist life science investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). Skye expects interim and topline data from its Phase 2 study in 2025.
Skye Bioscience, Inc.
11250 El Camino Real
Suite 100
San Diego, CA 92130
SKYE Investor Relations
T: (858) 410-0266
ir@skyebioscience.com
ClearTrust, LLC
16540 Pointe Village Dr.
Suite 210
Lutz, FL 33558
T: 813-235-4490
www.ClearTrustOnline.com
Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.